Alterations of the Arginine Metabolome in Asthma by Abigail Lara et al.
Alterations of the Arginine Metabolome in Asthma
Abigail Lara1*, Sumita B. Khatri1,2*, Zeneng Wang3, Suzy A. A. Comhair1,4, Weiling Xu1, Raed A. Dweik1,4,
Melanie Bodine3, Bruce S. Levison3, Jeffrey Hammel1, Eugene Bleecker5, William Busse6, William J. Calhoun7,
Mario Castro8, Kian Fan Chung9, Douglas Curran-Everett10, Benjamin Gaston11, Elliot Israel12, Nizar Jarjour6,
Wendy Moore5, Stephen P. Peters5, W. Gerald Teague13, Sally Wenzel14, Stanley L. Hazen3, and
Serpil C. Erzurum1,4, for the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program**
1Department of Pathobiology, Cleveland Clinic, Cleveland, Ohio;
2Pulmonary and Critical Care Medicine, MetroHealth Medical Center, Cleveland,
Ohio; Departments of
3Cell Biology, and
4Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, Ohio;
5Wake Forest University,
Winston-Salem, North Carolina;
6University of Wisconsin, Madison, Wisconsin;
7University of Texas, Galveston, Texas;
8Washington University in St.
Louis, St. Louis, Missouri;
9Imperial College School of Medicine, London, United Kingdom;
10National Jewish Medical and Research Center, Denver,
Colorado;
11University of Virginia, Charlottesville, Virginia;
12Brigham and Women’s Hospital, Boston, Massachusetts;
13Emory University, Atlanta,
Georgia; and
14University of Pittsburgh, Pittsburgh, Pennsylvania
Rationale: As the sole nitrogen donor in nitric oxide (NO) synthesis
and key intermediate in the urea cycle, arginine and its metabolic
pathways are integrally linked to cellular respiration, metabolism,
and inﬂammation.
Objectives:Wehypothesizedthatarginine(Arg)bioavailabilitywould
beassociatedwithairﬂowabnormalitiesandinﬂammationinsubjects
with asthma, and would be informative for asthma severity.
Methods: Arg bioavailability was assessed in subjects with severe and
nonsevere asthma and healthy control subjects by determination of
plasmaArgrelativetoitsmetabolicproducts,ornithineandcitrulline,
and relative to methylarginine inhibitors of NO synthases, and by
serum arginase activity. Inﬂammatoryparameters,including fraction
of exhaledNO(FENO), IgE, skintest positivity to allergens, bronchoal-
veolar lavage, and blood eosinophils, were also evaluated.
Measurementsand Main Results: Subjectswith asthmahadgreaterArg
bioavailability, but also increased Arg catabolism compared with
healthy control subjects, as evidenced by higher levels of FENO and
serum arginase activity. However, Arg bioavailability was positively
associated with FENO only in healthy control subjects; Arg bioavail-
ability was unrelated to FENO or other inﬂammatory parameters in
severe or nonsevere asthma. Inﬂammatory parameters were related
to airﬂow obstruction and reactivity in nonsevere asthma, but not in
severe asthma. Conversely, Arg bioavailability was related to airﬂow
obstructioninsevereasthma,butnotinnonsevereasthma.Modeling
conﬁrmed that measures of Arg bioavailabilty predict airﬂow ob-
struction only in severe asthma.
Conclusions:UnlikeF ENO,Argbioavailabilityisnotasurrogatemeasure
of inﬂammation; however, Arg bioavailability is strongly associated
with airﬂow abnormalities in severe asthma.
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Model systems of allergic airway inﬂammation and studies in
humanasthmarevealthatalterationsin L-arginineandnitricoxide
(NO [nitrogen monoxide]) metabolic pathways in the lung play
a role in asthma pathophysiology (1–10). Arginine (Arg), a semi-
essential amino acid, is used in protein synthesis, but is also an
important substrate for enzymes such as the NO synthases (NOS)
and arginases (4, 11–13). These intracellular catabolic enzymes of
Arg are induced simultaneously in various conditions of inﬂam-
mation, but the activity of the enzymes are regulated by Arg
availability(5).ArginasesconvertArgtoornithine(Orn)andurea,
whereas NOS convert Arg to citrulline (Cit) in a reaction that
simultaneously produces NO (14). NOS type 2 expression in the
airwayandNOinexhaledbreatharegenerallyhigherthannormal
insubjects withasthma(15–17). Patients withasthmawho present
with acute asthma exacerbation have higher arginase activity and
lower levels of Arg as compared with healthy control subjects (1).
Twoisoformsofarginaseenzymesmaycontributetototalarginase
activity levels. Arginase I is highly expressed in the liver, where it
serves a key role in the urea cycle, but also in cells that lack
acompleteureacycle,whichsuggestsothermetabolicfunctionsin
nonhepatic tissues (18). Arginase II is present in most tissues,
including lung, and localized to the mitochondria within the cell
(4, 19, 20). Greater lung expression of both the arginase I and II
genetranscriptsispresentinthemurinemodelofallergicasthmaas
compared with control mice (5, 21). The guinea pig model of
allergicasthmaconﬁrmsthatarginaseactivityincreasesduringthe
early response to allergen (2). In the murine model of asthma,
greater Arg metabolism through arginases has been deﬁnitively
linkedtothedevelopmentofairwayhyperreactivity(3),suggesting
that Arg levels and its utilization by speciﬁc pathways may serve
as determinants in the physiologic characteristics that typify
humanasthma.However,althoughgeneticstudiesinhumanshave
reported that arginase I and II single-nucleotide polymorphisms
areassociatedwithanincreasedrelativeriskforasthmaandatopy,
the effect of polymorphisms on arginase expression or functional
activity in humans is unknown (22).
AT A GLANCE COMMENTARY
Scientiﬁc Knowledge on the Subject
Studies suggest that alterations in arginine (Arg) metabolic
pathways, such as the arginases and nitric oxide (NO)
synthases, play a role in asthma pathophysiology.
What This Study Adds to the Field
In this study, we show that quantitative assessment of
metabolites critical to Arg and NO pathways are informa-
tive for determination of airﬂow abnormalities linked to
remodeling in severe asthma.
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Internet address: www.atsjournals.orgIn addition to arginine catabolism by NOS and arginases, the
lung has another essential role in regulation of Arg metabolism
via the production and clearance of methylarginines (23).
Methylated Arg is produced by a post-translational modi-
ﬁcation of proteins by Arg methyltransferases (24). Once
methylated, protein degradation releases the methylated argi-
nines. The asymmetric methylarginines asymmetric dimethyl-
arginine (ADMA) and monomethylarginine (MMA) may
compete with Arg and serve as endogenous inhibitors of NOS
(25). Symmetric dimethylarginine (SDMA), although not an
NOS inhibitor, competes with Arg for the cationic amino acid
transporter, and thus can potentially modulate intracellular Arg
bioavailability (25). Efﬁcient clearance mechanisms for meth-
ylarginines are present in the lung or kidney (in the case of
SDMA), and maintain substrate availability to NOS and
arginases under homeostatic conditions of health; however,
higher levels of methylarginines in disease may reduce and/or
redirect Arg metabolism (23, 25). Global functional Arg bio-
availability for arginases and NOS, which are intracellular
enzymes, may be assessed by the ratio of plasma Arg to its
enzymatic and/or metabolic products (i.e., Arg relative to the
sum of Orn and Cit, and Arg-to-methylarginine ratios).
Altogether, these studies indicate that the lung is a critical
organ for regulation of Arg metabolism, and that alterations in
Arg metabolism may be informative for asthma. In support of this
concept, increased levels of exhaled NO serves as a sensitive and
speciﬁc biomarker of airway inﬂammation, reactivity, and airﬂow
limitation in asthma (15–17, 26–33). Thus, we hypothesized that
the quantitative assessment of Arg bioavailability would be
associated with airﬂow abnormalities and inﬂammation, and that
parametersofArgmetabolismandbioavailabilitymightdiscrim-
inate among severe and nonsevere asthma phenotypes (34). To
test this, plasma Arg, Orn, Cit, endogenous methylarginines, and
steady-state Arg bioavailability, as assessed by ratio of Arg to
products generated from enzymatic catabolism (Arg/[Orn 1
Cit]) and by ratio of Arg to its methylated forms, along with
arginaseactivity,weredeterminedinparticipantswithsevereand
nonsevereasthmaandhealthycontrolsubjectswhowereenrolled
in the National Heart Lung Blood Institute–sponsored multicen-
ter Severe Asthma Research Program (SARP). Traditional
inﬂammatory parameters, including fraction of exhaled NO
(FENO), IgE, skin test positivity to allergen, bronchoalveolar
lavage (BAL), and blood eosinophils, were also evaluated. The
ﬁndings reveal that subjects with asthma have increased systemic
Arg catabolism, but still maintain greater Arg bioavailability as
compared with healthy control subjects. Although quantitative
assessment of the Arg metabolome was not related to inﬂamma-
tion in asthma, the ﬁnding of a selective relationship of Arg
bioavailability to airﬂow obstruction in severe asthma supports
the concept of a severe asthma phenotype distinct from non-
severe asthma (35).
METHODS
Subject Enrollment, Characterization, and Samples
AllsubjectswererecruitedbycentersparticipatingintheSARP(34,36),
and gave written informed consent by signing a consent document ap-
proved by the institutional review board at the enrolling center and the
SARPDataSafetyandMonitoringBoard.Severeasthmawasdeﬁnedby
majorandminorcriteria,asdescribedbytheProceedingsoftheAmerican
Thoracic Society Workshop on Refractory Asthma (37). Subjects en-
rolled in SARP were classiﬁed as healthy control subjects, subjects with
nonsevereasthma,orthosewithsevereasthma.Healthycontrolsubjects
lacked any cardiopulmonary symptoms, and had normal baseline
spirometry and negative methacholine challenge testing (34, 36). Exclu-
sioncriteriaforsubjectswithasthmaandhealthycontrolsubjectsincluded
havinganyoneofthefollowing:currentsmoking,smokingwithinthe past
year, former smokers with >5 pack-year total history, and pregnancy.
In most cases, participants underwent blood draw and lung functions
on the same day; otherwise, lung function testing and FENO that were
closesttothetimeatwhichbloodwasdrawnwasusedforanalyses.Blood
wasobtainedbyvenipuncturefromparticipants,separatedintoserumor
plasma by centrifugation, then aliquotted into 1-ml samples for storage
at 2808C until time of shipment on dry ice by overnight courier to the
Cleveland Clinic laboratory for processing.
A subgroup of participants underwent bronchoscopy for BAL. BAL
was performed by a standardized protocol at all centers. Two 50-ml
aliquots of normal saline warmed to 378C were instilled using hand pres-
sureonasyringeandrecoveredbyhandsuctiononealiquotatatime.The
return BAL was pooled, centrifuged, and the resulting cell pellet re-
suspendedand cytospinprepared. Differentialcellcountwas performed
using Diff-Quik stain (Thermo Fisher Scientiﬁc, Swedesboro, NJ).
Lung Function and FENO
Spirometry was performed with an automated spirometer, consistent
with American Thoracic Society standards (38). Measurements of
lung function were collected for each of three or more efforts before
and after the administration of two puffs (180 mg) of albuterol.
Reference equations for spirometry were from the third National
Health and Nutrition Examination Survey (NHANES III). Methacho-
line challenge testing was performed only on volunteers with baseline
FEV1 greater than 55%.
FENO was measured by an online method at a constant ﬂow rate of
50 ml/second according to the standards published by the American
Thoracic Society (39, 40). Lung function and FENO were performed on
the same day.
Arginase Activity
Arginase activity was performed using aliquots of 50 ml of serum and
measuredbytheconversionof[14C]guanidine-L-arginine(PerkinElmer,
Waltham, MA and American Radiolabeled Chemicals, St. Louis, MO)
to [14C]urea, which was then converted to [14CO2] by urease and
subsequently trapped as Na2
14CO3 and measured by scintillation count-
ing (LS 6000; Beckman-Coulter, Fullerton, CA) (41). Unit of arginase
activity is deﬁned as mmol urea formed 3 minute21.
Arg, Orn, Cit, ADMA, MMA, and SDMA Analyses
Quantiﬁcation of Arg, Cit, Orn, ADMA, MMA, and SDMA in ethyl-
enediaminetetraacetic acid plasma were performed using stable isotope
dilution HPLC with online electrospray ionization tandem mass spec-
trometry (ESI/MS/MS) using an API 365 triple quadrupole mass
spectrometer (Applied Biosystems, Foster City, CA) equipped with
Ionics EP 101 upgrade (Concord, ON, Canada) and interfaced with
a Cohesive HPLC (Franklin, MA), as previously described (42). Brieﬂy,
[13C6]-Arg was added as internal standard, and then proteins were
precipitated with acetonitrile. Acetonitrile was removed under vacuum,
residue resuspended, and levels of amino acids quantiﬁed by high
performanceliquidchromatographywithon-lineelectrosprayionization
tandemmassspectrometryanalysis.Aminoacidswereresolvedona2503
4.6 mm Rexchrom S5-100-P phenyl column (Regis Chemical, Morton
Grove,IL)usingadiscontinuousgradientwith0.2%formicacid(solvent
A), 10 mM ammonium formate in methanol (solvent B), and 10 mM
ammonium formate in water (solvent C). The gradient used was as
follows: thecolumnwas ﬁrstequilibratedwith 100%solventA at800ml/
minuteandheldatthiscompositionfor0.5minutesaftertheinjection.A
linear gradient was then run to 25% solvent B, 25% solvent C (50%
solventA),overthenext3minutesandheldfor8minutesataﬂowrateof
800 ml/minute. At 11.5 minutes, the ﬂow rate was increased to 1,000 ml/
minute and the solvent composition was changed to 100% solvent B in
a linear fashion over 2.5 minutes, held at 100% solvent B for 3 minutes,
and then changed to 100% solvent C at 1,000 ml/minutes for 3 minutes.
MassspectrometricanalyseswereperformedonlineusingESI/MS/MSin
the positive ion mode with multiple reaction monitoring, using unique
characteristic parent/daughter ion transitions for each analyte. Cone
potentials and collision energy were optimized for each analyte, and
standard curves generated with [13C6]-Arg as internal standard. Each
analyte monitored demonstrated near quantitative recovery, good
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intra- and interassay coefﬁcients of variance of less than 10%.
Statistical Analysis
DataaresummarizedusingthemeananditsSE.Student’sttestisusedto
compare subjects with asthma and healthy control subjects, as well as
subjects with severe and nonsevere asthma with respect to quantitative
patient characteristics, clinical parameters, levels of amino acids, argi-
nase, and FENO. In situations in which the quantitative data are not
normally distributed, a nonparametric Wilcoxon rank sum test is used.
Group comparisons with respect to categorical variables are performed
usingchi-squaretestsor,alternatively,Fisher’s exacttestwhenexpected
cell counts were less than 5. Associations between quantitativevariables
are assessed using Spearman correlations. Linear regression modeling,
controlling for various factors, including age, sex, and systemic cortico-
steroid use, is used to determine differences in covariate-adjusted mean
values of inﬂammatory and metabolic parameters among the three
groups, and also between severe and nonsevere asthma. Tukey’s
adjustment for multiple comparisons was performed with the three-
group comparisons.To determinewhether theobserved relationshipfor
arginase and Arg bioavailability and airﬂow in severe asthma was
different than those in nonsevere asthma, linear regression modeling
withinteractiontermsaccountingfordifferenceinslopesofrelationships
between the asthma groups was performed. Multivariable linear re-
gressionanalyseswerealsoperformedtoinvestigatetheabilitytopredict
degree of airﬂow obstruction in asthma. Statistical analyses were
performedwiththeJMPstatisticalprogram,version5.0,andSASversion
9.1 (SAS Institute, Inc., Cary, NC).
RESULTS
Complete analysis of the Arg metabolic pathways was per-
formed in 258 individuals (232 with asthma) enrolled in SARP.
VolunteercharacteristicsandlungfunctionsareshowninTable1.
Children (ages 6–17 yr; 30 subjects with asthma and 2 healthy
controlsubjects) are included within this population. A subgroup
of participants underwent BAL for cell differential counts (78
participants: 16 healthy control subjects, 41 with nonsevere
asthma, and 21 with severe asthma). Subjects with asthma had
high IgE levels, systemic leukocytosis with eosinophilia, eosino-
philia in BAL samples, and high FENO as compared with healthy
controlsubjects(Table1).Subjectswithasthmahadmorepositive
skin tests than healthy control subjects, and subjects with non-
severe asthma had more positive skin tests than subjects with
severe asthma. As expected based on classiﬁcation of severity,
subjects withsevere asthma weremorelikelytobe oninhaled and
systemiccorticosteroidsascomparedwithsubjectswithnonsevere
asthma (Table 2). Eosinophilia in blood or BAL, and FENO,w e r e
similar among subjects with severe and nonsevere asthma.
Arginase Activity
Mean arginase activity of all subjects with asthma (0.6 6 0.1
mmol/ml/h) was greater than that of healthy control subjects
(0.25 6 0.03 mmol/ml/h), with a signiﬁcantly larger number of
high arginase values (above 0.65 mmol/ml/h, the highest value
measuredinourhealthycontrolgroup)inallsubjectswithasthma
compared with control subjects (40/211 5 19% compared with
0/22 5 0%, respectively; Fisher’s P 5 0.018). Arginase activity of
subjects with nonsevere asthma (0.72 6 0.16 mmol/ml/h) was not
signiﬁcantly different from that of subjects with severe asthma
(0.39 6 0.05 mmol/ml/h) (P 5 0.12), even when controlling for
age, sex, and corticosteroid use among subjects with nonsevere
and severe asthma (P 5 0.57).
The Arg Metabolome: Arg, Orn, Cit, and Methylarginines
Plasma concentrations of Arg, Orn, Cit, ADMA, SDMA, and
MMA were not signiﬁcantly different among healthy control
subjects and subjects with asthma as a group (all P values . 0.05,
controlling for age, sex, and systemic corticosteroid use), al-
though Orn tended to be lower in asthma (Orn: healthy control
TABLE 1. FEATURES OF STUDY PARTICIPANTS
Patient Characteristics Control Subjects Subjects with Asthma P Value* Nonsevere Severe P Value
†
n 26 232 148 84
Mean age, yr 30 (2) 35 (1) 0.04 33 (1) 38 (2) ,0.01
Sex, male:female 8:18 75: 157 43: 105 32:52
Ethnicity, W/AA/other 24/0/2 216/8/8 142/5/1 74/3/7
Lung function
FEV1, L 3.67 (0.12) 2.46 (0.06) ,0.001 2.70 (0.07) 2.0 (0.1) ,0.001
FEV1 % predicted 102 (2) 77 (1) ,0.001 84 (1) 66 (2) ,0.001
FVC, L 4.90 (0.23) 3.74 (0.07) ,0.001 3.84 (0.09) 3.57 (0.09) ,0.001
FVC % predicted 104 (3) 90 (1) ,0.001 94 (1) 83 (2) ,0.001
FEV1:FVC ratio 0.82 (0.01) 0.71 (0.01) ,0.01 0.74 (0.01) 0.65 (0.01) ,0.001
FENO, ppb 14.0 (1.7) 38.0 (2.8) ,0.001 41.7 (4.0) 31.6 (3.3) 0.292
Blood work
Total WBCs 3 106 (serum) 5.56 (0.25) 7.08 (0.15) ,0.001 7.00 (0.16) 7.22 (0.28) 0.941
Eosinophils, %
‡ 2.0 (0.3) 4.4 (0.3) ,0.0001 4.2 (0.3) 4.6 (0.6) 0.912
IgE, IU/ml 48 (16) 362 (59) ,0.0001 294 (32) 482 (153) 0.310
BAL, %x
Macrophages 94.3 (1.51) 83.0 (3.36) 0.144 79.28 (4.82) 90.68 (1.70) 0.369
Neutrophils 1.90 (0.78) 2.83 (0.66) 0.991 2.71 (0.90) 3.09 (0.83) 0.287
Eosinophils 0.07 (0.07) 1.31 (0.26) 0.009 1.16 (0.34) 1.63 (0.39) 0.179
Lymphocytes 3.73 (0.97) 5.48 (0.75) 0.877 5.84 (1.00) 4.75 (1.04) 0.915
Allergen skin test
No. of positive skin tests/12 0.8 (0.5) 3.8 (0.2) ,0.0001 4.2 (0.24) 3.12 (0.30) 0.01
<3 Positive skin tests/12k 25 119 67 52
.3 Positive skin tests/12k 1 113 81 32
Deﬁnition of abbreviations:A A5 African American; BAL 5 bronchoalveolar lavage; FENO 5 fraction of exhaled nitric oxide; W 5 white; WBCs 5 white blood cells.
Results are displayed as mean (SE) unless otherwise noted.
* P value, control versus asthma.
† P value, nonsevere versus severe asthma, Wilcoxon rank sum test for nonparametric data.
‡ Eosinophils as a percentage of total WBCs.
x BAL data available in 16 control subjects, 41 individuals with nonsevere asthma, and 21 individuals with severe asthma.
k Median number of skin tests positive in study was three.
Lara, Khatri, Wang, et al.: Arginine in Asthma 675subjects, 23 6 2 mM; all asthma, 19.4 6 0.9 mM; P 5 0.06).
However,whenArgavailabilityforcellularutilizationwasevaluated
by the ratio of Arg to products generated from enzymatic catabo-
lism (Arg/[Orn 1 Cit]) and by its relationship to its inhibitory
methylated forms (Arg/methylarginines), the asthma group had
greater Arg availability compared with healthy control subjects
(Arg/[Orn 1 Cit]: control subjects, 0.84 6 0.07; asthma, 1.03 6
0.04; P 5 0.03; Arg/methylarginine: control subjects, 64 6 5;
asthma, 76 6 2; P 5 0.053).
Given the differences among asthma and healthy control sub-
jects, we evaluated Arg and its products among the severe and
nonsevere asthma groups (Table 3). Levels of methylarginines
were signiﬁcantly different among control subjects and severe
and nonsevere asthma groups (Table 3). Methylarginines were
higher in severe than nonsevere asthma, even after adjusting for
age, sex, and systemic corticosteroid use (Table 3). The greater
methylargininelevelsinsevereasthma,despiteoverall greaterArg
availability in asthma collectively, could suggest potential interfer-
ence with intracellular Arg utilization in severe asthma.
Arg Availability for NO Synthesis
Studies indicate that arginase and methylarginines may limit Arg
availability for NO synthesis by NOS (9, 13, 43). To estimate
whether the serum arginase activity or plasma methylarginine
levels reﬂect intracellular Arg utilization by NOS, FENO was
evaluated as a function of parameters of Arg availability and
arginase activity. As anticipated, all parameters of Arg substrate
availabilityforNOScorrelateddirectlytoFENOinhealthycontrol
subjects(Table4).Greaterarginaseactivitywouldleadtogreater
Orn production; thus, the trend for an inverse relationship of
serum arginase activity to Arg/(Orn 1 Cit) was expected in
healthy control subjects (P 5 0.08).
In contrast to the ﬁndings in healthy control subjects, the
nonsevere asthma group tended to have a correlation between
FENO and only one parameter of Arg availability (Arginine:inhi-
bitory methylarginine ratio) (P 5 0.053) (Table 4). The severe
asthma group had no signiﬁcant association of FENO to Arg
parameters (Table 4). On the other hand, the severe asthma
group had a signiﬁcant inverse correlation of serum arginase
activity to Arg/(Orn 1 Cit), possibly suggesting greater inﬂuence
of arginase on intracellular Arg utilization in severe asthma. The
strongrelationshipofallparametersofArgavailabilitytoFENOin
healthycontrolsubjects,andtherelationshipofArg/(Orn1Cit)to
arginaseactivity in severe asthma, provides some conﬁdence that
the circulating levels of Arg and its metabolic products do reﬂect
intracellular Arg utilization. The lack of relation between FENO
and Arg availability in asthma suggests that intracellular Arg
metabolism is altered in asthma.
Relationship of Arg Bioavailability and Arginase Activity to
Inﬂammatory Parameters and Lung Function
Asinpreviousstudies(15,44,45),FENOinnonsevereasthmawas
directly related to parameters of inﬂammation (FENO correlation
to: number of positive skin tests, R 5 0.29, P , 0.0001; IgE, R 5
0.34, P , 0.0001; blood eosinophils, R 5 0.221, P 5 0.005).
However, FENO was not associated with inﬂammatory parame-
tersinsevereasthma(allP.0.1).Arginaseactivityandmeasures
of Arg availability were generally unrelated to all parameters of
inﬂammation(skintestpositivity,BALorbloodeosinophils,and
FENO)withinthesevereornonsevereasthmagroups(allP.0.1),
except for an association within the nonsevere asthma group of
IgEtoArg/(Orn1Cit)(R50.28,P50.03)andtoArg/(ADMA1
MMA 1 SDMA) (R 5 0.34, P 5 0.01). Thus, Arg bioavailability
and arginase, unlike FENO, were not related to traditional
markers of inﬂammation in asthma, and were not surrogates for
exhaled NO measure.
FENO was associated with worse airﬂow and greater hyper-
responsiveness within the nonsevere asthma group, but was
unrelated to hyperresponsiveness or airﬂow measures in severe
asthma (Table 5). In contrast, arginase activity was inversely
TABLE 2. MEDICATION USE BY ALL PARTICIPANTS WITH
ASTHMA AND BY SEVERITY
Asthma Nonsevere Asthma Severe Asthma
Type of Medication (n 5 232)( n 5 148)( n 5 84)
Inhaled corticosteroids* 169 (72.8%) 89 (60.1%) 80 (95.2%)
†
Oral corticosteroids 42 (18.1%) 10 (6.8%) 32 (38.1%)
†
Injected corticosteroids 7 (3.0%) 0 7 (8.3%)
†
Inhaled b-agonist 1
corticosteroid
130 (56.0%) 66 (44.6%) 64 (76.2%)
†
Results shown here are based on responses to question: ‘‘Have you used
medication to treat your breathing problems in the last 3 months? If yes mark all
that apply.’’ Values in parentheses are percentages.
* Deﬁned as either in combination with long-acting b-agonist or alone.
† P , 0.01 with Wilcoxon rank sum test comparing medication use of
individuals with severe asthma to those with nonsevere asthma.
TABLE 3. Arg AVAILABILITY BY PRESENCE OF ASTHMA AND ASTHMA CATEGORY
Asthma Status
Among All Groups
Severe vs. Nonsevere
Asthma
Metabolic Parameter Healthy (Control) Nonsevere Asthma Severe Asthma P Value* P Value
† P Value
‡
Arg, mM 37.9 (3.35) 41.1 (2.40) 41.1 (2.40) 0.618 0.17 0.79
Orn, mM 23.1 (1.9) 19.1 (1.2) 20.0 (1.2) 0.167 0.23 0.96
Cit, mM 25.4 (3.1) 22.0 (1.1) 26.6 (1.9) 0.088 0.034 0.17
MMA, mM 0.044 (0.002) 0.040 (0.002) 0.052 (0.004) 0.012 0.006 0.037
ADMA, mM 0.331 (0.028) 0.290 (0.011) 0.346 (0.021) 0.038 0.067 0.05
SDMA, mM 0.219 (0.013) 0.190 (0.006) 0.229 (0.013) 0.012 0.021 0.025
Arg/(Orn 1 Cit) 0.843 (0.069) 1.048 (0.052) 0.997 (0.058) 0.104 0.43 0.9
Arg/(MMA 1 ADMA) 105.2 (8.4) 124.2 (4.9) 116.0 (6.0) 0.178 0.23 0.7
Arg/(MMA 1 ADMA 1 SDMA) 64.5 (4.7) 78.0 (3.2) 72.3 (3.5) 0.101 0.17 0.6
Deﬁnition of abbreviations: ADMA 5 asymmetric dimethyl arginine; Arg 5 arginine; Cit 5 citrulline; MMA 5 monomethylarginine; Orn 5 ornithine; SDMA 5
symmetric dimethyl arginine.
Data in left columns are presented as mean (SE). Values in bold indicate R values of spearman correlations with signiﬁcant P , 0.05.
* P value from linear modeling, controlling for age, sex, systemic corticosteroid use; systemic corticosteroid use is deﬁned as ‘‘yes’’ to receives oral or intravenous
corticosteroids at least monthly.
† P value for severe vs. nonsevere based on Wilcoxon rank sum test.
‡ P value from linear modeling with Tukey adjustment for multiple pairwise comparisons between control subjects, individuals with nonsevere asthma, and those with
severe asthma.
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(Figure 1 and Table 5). Likewise, greater Arg availability was
strongly associated with better airﬂow within the severe asthma
group (Table 5 and Figure 1), but unrelated to airﬂow in
nonsevere asthma (Table 5). Arginase activity and Arg avail-
ability were also related to bronchodilator response in severe
asthma (Table 5).
To determine whether the observed relationship for arginase
andArgbioavailabilitytoairﬂowinsevereasthmaissigniﬁcantly
differentthannonsevereasthma,linearregressionmodelingwith
interaction terms accounting for difference in slopes of relation-
ships between the asthma groups was performed. There was
a trend toward signiﬁcance for the difference in slopes of the
relationships of arginase activity and airﬂow between nonsevere
and severe asthma groups (P 5 0.10). There was a signiﬁcant
differenceintheslopesoftherelationshipsofArgavailabilityand
airﬂow between severe and nonsevere asthma (P 5 0.01).
To explore the association of Arg bioavailability, inﬂamma-
tion, and airﬂow obstruction, multivariable linear regression
analyses were performed for ability to predict degree of airﬂow
obstruction in asthma. We modeled lung function parameters of
FEV1, % predicted (%FEV1) and/or FEV1:FVC ratio using
parameters that reﬂect inﬂammation and atopy (FENO, BAL
eosinophilia, blood eosinophilia, IgE) and Arg bioavailability
(Arg/[Orn 1Cit], Arg/[MMA 1ADMA]). Arg/(Orn 1 Cit)and
Arg/(MMA 1 ADMA) provided a model predictive of %FEV1
for severe asthma (R2 5 0.41, P 5 0.0002; Figure 2A). Using the
same variables, FENO, Arg/(Orn 1 Cit), and Arg/(MMA 1
ADMA) were found to be predictive of FEV1/FVC in severe
asthma(R250.30,P 50.009;modelterms,estimates[SE],andP
values: intercept 0.479 [0.069], P , 0.0001; FENO, 20.00093
[0.00087], P 5 0.29; Arg/[Orn 1 Cit], 0.108 [0.052], P 5 0.04;
and Arg/[MMA 1 ADMA], 0.00078 [0.0005], P 5 0.15). In
nonsevere asthma, using the same variables, a signiﬁcant model
could not be derived to predict %FEV1 or FEV1/FVC (all P .
0.1). This preliminary predictive model supports the conclusion
that Arg bioavailability is uniquely associated with airﬂow
obstruction in severe asthma.
DISCUSSION
A wealth of studies conﬁrms that the NO/arginine pathway plays
a role in the inﬂammation and injury of the asthmatic airway (21,
26, 27, 46, 47). Recent studies also suggest that the arginase/Arg
pathway may be coordinately involved in asthma (1, 8, 21, 22).
The current study extends our understanding of Arg metabolic
pathways in asthma. First, the results reveal that subjects with
asthma have higher arginase activity and FENO than healthy
control subjects, which veriﬁes that asthma is a disease charac-
terized by increased Arg catabolism (Figure 2B), but assessment
of steady-state bioavailability of Arg using the ratio of Arg-to-
endproducts suggests that subjects with asthma are still able to
TABLE 4. CORRELATIONS BETWEEN EXHALED NO, ARGINASE
ACTIVITY, AND Arg AVAILABILITY AMONG HEALTHY CONTROL
SUBJECTS AND SUBJECTS WITH ASTHMA
Healthy Control
Nonsevere
Asthma Severe Asthma
Metabolic
Parameter Statistic* FENO Arginase FENO Arginase FENO Arginase
Arginase activity R 20.309 — 0.103 — 0.164 —
P 0.198 — 0.224 — 0.176 —
Arg R 0.226 20.224 0.061 20.142 20.110 20.131
P 0.399 0.485 0.635 0.302 0.512 0.541
Arg/(Orn 1 Cit) R 0.624 20.524 0.023 20.166 20.275 20.466
P 0.010 0.080 0.859 0.227 0.094 0.022
Arg/(MMA 1
ADMA)
R 0.656 0.147 0.247 20.027 0.191 0.067
P 0.006 0.649 0.053 0.842 0.251 0.754
Arg/(MMA 1
ADMA 1 SDMA)
R 0.585 20.098 0.198 20.114 0.136 20.185
P 0.017 0.762 0.122 0.408 0.415 0.386
Deﬁnition of abbreviations: ADMA 5 asymmetric dimethyl arginine; Arg 5
arginine; Cit 5 citrulline; FENO 5 fraction of exhaled nitric oxide; MMA 5
monomethylarginine; Orn 5 ornithine; SDMA 5 symmetric dimethylarginine.
Values in bold indicate R values of Spearman correlations with signiﬁcant
P , 0.05.
* R and P values represent Spearman correlation coefﬁcient and signiﬁcance,
respectively.
TABLE 5. CORRELATIONS AMONG LUNG FUNCTIONS, INFLAMMATORY PARAMETERS, AND Arg AVAILABILITY
Nonsevere Asthma Severe Asthma
Parameters Statistic* %FEV1 %DFEV1 FEV1/FVC PC20 %FEV1 %DFEV1 FEV1/FVC PC20
Inﬂammatory
Eosinophils in blood, % R 20.124 0.122 20.063 20.271 0.036 20.023 0.025 20.171
P 0.122 0.129 0.434 0.001 0.743 0.832 0.819 0.220
Eosinophils in BAL, % R 20.272 0.126 20.373 20.204 0.109 20.181 20.130 20.273
P 0.086 0.433 0.017 0.212 0.638 0.446 0.574 0.325
IgE R 20.055 0.159 20.141 20.244 20.026 0.072 20.021 20.211
P 0.495 0.046 0.076 0.004 0.811 0.509 0.847 0.129
No. of positive skin tests R 20.175 20.169 20.238 20.173 20.118 0.094 20.278 20.019
P 0.027 0.034 0.002 0.040 0.272 0.387 0.021 0.906
FENO, ppb R 0.147 0.175 20.223 20.318 20.111 0.069 20.184 0.186
P 0.063 0.028 0.005 0.0001 0.302 0.523 0.086 0.177
Metabolic
†
Arginase activity R 0.051 20.120 21.083 0.042 20.337 0.242 20.278 20.019
P 0.546 0.160 0.330 0.637 0.005 0.047 0.021 0.906
Arg/(Orn 1 Cit) R 20.029 20.016 0.183 0.378 0.468 20.316 0.447 20.268
P 0.820 0.903 0.154 0.006 0.004 0.057 0.006 0.241
Arg/(MMA 1 ADMA) R 20.164 0.034 20.073 0.15 0.283 20.259 0.280 20.010
P 0.203 0.793 0.575 0.293 0.089 0.122 0.094 0.964
Deﬁnition of abbreviations: ADMA 5 asymmetric dimethylarginine; Arg 5 arginine; BAL 5 bronchoalveolar lavage; Cit 5 citrulline; FENO 5 fraction of exhaled nitric
oxide; MMA 5 monomethylarginine; Orn 5 ornithine; PC20 5 provocative concentration of methacholine causing a 20% fall in FEV1;% DFEV1 5 % change in FEV1;
%FEV1 5 FEV1, % predicted; SDMA 5 symmetric dimethylarginine.
Values in bold indicate R values of Spearman correlations with signiﬁcant P , 0.05.
* R and P values represent Spearman correlation coefﬁcient and signiﬁcance, respectively.
† Metabolic parameters are measured in serum.
Lara, Khatri, Wang, et al.: Arginine in Asthma 677maintain a balance of greater Arg availability than healthy
controlsubjects.Contrarytothehypothesis,measuresofarginase
and Arg availability are not synonymous with measures of
exhaled NO in asthma, and do not serve as surrogate biomarkers
ofinﬂammation.Thesevereasthmagrouphadincreasedlevelsof
methylarginines compared with the nonsevere asthma group,
which indicates a change in Arg metabolism, and perhaps less
availability of Arg for intracellular NOS utilization. Differences
in corticosteroid usage and age among subjects with severe and
nonsevere asthma may contribute to the alterations in Arg
metabolism, but, nevertheless, parameters of Arg bioavailability
are uniquely predictive of airﬂow obstruction in severe asthma
and disconnected from inﬂammation (1, 5).
Subjectswithasthmaexperiencingexacerbationsandpresent-
ing acutely to the emergency room have greater serum arginase
activity compared with control subjects without asthma, and, in
asmallsubgroupoftheseindividuals,treatmentdecreasesarginase
activity (1). In the current study, although not undergoing acute
exacerbation, subjects with severe and nonsevere asthma have
greaterarginaseactivitythancontrolsubjects.Subgroupanalyses
suggeststhattheconditionofasthmaitselfwasthedeterminantof
arginase activity differences among healthy control subjects and
subjects with asthma, but the inability to control for variable
corticosteroid dosage was a limitation in the analyses. In other
studies,arginasegenesarestronglyinducedinexperimentalmodels
of allergen-induced asthma (2, 4, 5, 21, 48). Arginase I is strongly
induced by Th2 cytokines, such as IL-4 and IL-13, which are
increased in asthma and related to the atopic phenotype (49–51).
These studies suggest that arginase expression and activity is
a downstream consequence of allergen-induced gene activation
in asthma (52). Here, subjects with severe and those with non-
severe asthma had evidence of atopic inﬂammation with BAL
and blood eosinophilia, high levels of IgE, and skin test positivity
to allergens, which may have inﬂuenced arginase activity, but no
Figure 1. Arginase activity (left panels), arginine (Arg)
availability (right panels), and lung function in the group
of severe asthma. Arginase activity is inversely related to
lung function (FEV1, % predicted [%FEV1], top panels;
FEV1/FVC, bottom panels). In contrast, Arg availability as
measured by Arg/endproduct ratio (Arg/[ornithine (Orn) 1
citrulline (Cit)]) shows that greater Arg availability corre-
lates with better lung function.
Figure 2. (A) Model of airﬂow ob-
struction in severe asthma. Multivari-
able linear regression analyses were
performed to model lung function
parameter of %FEV1 in severe asthma
using parameters that reﬂect inﬂam-
mation (fraction of exhaled NO, bron-
choalveolar lavage eosinophilia, blood
eosinophilia, IgE) and arginine bioavail-
ability (Arg/[Orn 1 Cit], Arg/[MMA 1
ADMA]) (where: ADMA 5 asymmetric
dimethyl arginine; Arg 5 arginine; Cit 5
citrulline; MMA 5 monomethylargin-
ine; Orn 5 ornithine). Arg/(Orn 1 Cit)
and Arg/(MMA 1 ADMA) provided
a model predictive of %FEV1 for se-
vere asthma. (B) Arg metabolic path-
ways. Arg, a semiessential amino acid,
is the substrate for nitric oxide syn-
thases (NOS) and arginases. Methyl-
arginines released during protein breakdown, such as ADMA, MMA symmetric dimethylarginine (SDMA), can inﬂuence Arg metabolism (e.g.,
ADMA and MMA competitively inhibit NO synthesis). Subjects with asthma have overall greater activation of both NOS and arginase pathways as
compared with healthy control subjects. Severe asthma is characterized by a unique Arg metabolic proﬁle that includes greater methylarginine levels
than nonsevere asthma.
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of inﬂammation.
Inthiscontext,alimitationofthestudyisthatserummeasures
maynotreﬂectpulmonaryorintracellularlevels.Forexample,al-
though circulating Arg levels are similar among control subjects
and those with asthma in this study, prior study shows that
bronchial epithelial cells from asthmatic airways have more than
threefold higher Arg levels compared with cells from healthy
controlsubjects(47).Ontheotherhand,thestrongcorrelationof
FENO to Arg availability in healthy control subjects, which is
expected, as Arg is the substrate for NOS (8, 13, 53, 54) (Figure
2B), validates that measures of the Arg metabolome in plasma
reasonably reﬂect Arg availability to intracellular enzymes. In-
terestingly,anassociationbetweenFENOandArgbioavailabilityis
not found in asthma, which might be due to multiple causes,
including dietary differences among participants, corticosteroid
effects, and/or changes in intracellular Arg and methylarginines
transport and metabolism. For example, environments with high
oxidative stress have beenshown to decrease the activity of a key
enzyme by which ADMA is metabolized—dimethylarginine dime-
thylaminohydrolase (DDAH) (55)—whereas the cationic trans-
porter for intracellular transport of Arg is induced in experimen-
tal models of allergen-induced asthma (2, 4, 5, 21, 48). Given the
oxidative stress in asthma (36), diminished metabolism of meth-
ylarginines may contribute to alterations in Arg metabolism,
particularly in severe asthma.
Oneofthe moreremarkableﬁndings in the presentstudyisthe
striking and unique relationship observed between quantitative
measures of lung function and serum arginase activity and indices
of Arg bioavailability in severe asthma. These results provide new
insights into metabolic mechanisms that may lead to airway
remodeling and obstruction in severe asthma (56). Results from
thecurrentstudyimplicatearginaseinairwayobstructioninsevere
asthma,whichmayoccurinpartthroughthewell-describedeffects
of arginase on cell proliferation (57). In general, arginase expres-
sion is limiting for polyamine synthesis via production of Orn, its
precursor (57). Polyamines are required for DNA synthesis and
cellproliferation(58,59),andforsynthesisofproline,theprecursor
for collagen production (60, 61). Consistent with the ﬁnding of
greater arginase activity in asthma in the current study, serum
levels of polyamines are elevated in subjects with asthma and in
experimental models of asthma (5, 62–65). Taken together with
previous studies, the present cross-sectional observational study
identiﬁes alterations of Arg metabolism in asthma. Arg bioavail-
abilityandarginaseareincreasedinasthma,butarenotbiomarkers
of inﬂammation, and are unrelated to NO, but rather, uniquely
track airﬂow abnormalities in severe asthma.
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